Patents by Inventor Sean V. Tavtigian
Sean V. Tavtigian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150177253Abstract: A specific region of chromosome 10 (10q23.3) has been implicated by series of studies to contain a tumor suppressor gene involved in gliomas, as well as a number of other human cancers. One gene within this region was identified, and the corresponding coding region of the gene represents a novel 47 kD protein. A domain of this product has an exact match to the conserved catalytic domain of protein tyrosine phosphatases, indicating a possible functional role in phosphorylation events. Sequence analyses demonstrated the a number of exons of the gene were deleted in tumor cell lines used to define the 10q23.3 region, leading to the classification of this gene as a tumor suppressor. Further analyses have demonstrated the presence of a number of mutations in the gene in both glioma and prostate carcinoma cells. Methods for diagnosing and treating cancers related to this tumor suppressor, designated as TS10q23.3, also are disclosed.Type: ApplicationFiled: February 10, 2015Publication date: June 25, 2015Inventors: Peter Steck, Mark Pershouse, Samar A. Jasser, Alfred W.K. Yung, Sean V. Tavtigian
-
Patent number: 8735066Abstract: A specific region of chromosome 10 (10q23.3) has been implicated by series of studies to contain a tumor suppressor gene involved in gliomas, as well as a number of other human cancers. One gene within this region was identified, and the corresponding coding region of the gene represents a novel 47 kD protein. A domain of this product has an exact match to the conserved catalytic domain of protein tyrosine phosphatases, indicating a possible functional role in phosphorylation events. Sequence analyses demonstrated the a number of exons of the gene were deleted in tumor cell lines used to define the 10q23.3 region, leading to the classification of this gene as a tumor suppressor. Further analyses have demonstrated the presence of a number of mutations in the gene in both glioma and prostate carcinoma cells. Methods for diagnosing and treating cancers related to this tumor suppressor, designated as TS10q23.3, also are disclosed.Type: GrantFiled: April 23, 2012Date of Patent: May 27, 2014Assignee: Board of Regents, The University of Texas SystemInventors: Peter Steck, Mark A. Pershouse, Samar A. Jasser, Alfred W. K. Yung, Sean V. Tavtigian
-
Publication number: 20120315631Abstract: A specific region of chromosome 10 (10q23.3) has been implicated by series of studies to contain a tumor suppressor gene involved in gliomas, as well as a number of other human cancers. One gene within this region was identified, and the corresponding coding region of the gene represents a novel 47 kD protein. A domain of this product has an exact match to the conserved catalytic domain of protein tyrosine phosphatases, indicating a possible functional role in phosphorylation events. Sequence analyses demonstrated the a number of exons of the gene were deleted in tumor cell lines used to define the 10q23.3 region, leading to the classification of this gene as a tumor suppressor. Further analyses have demonstrated the presence of a number of mutations in the gene in both glioma and prostate carcinoma cells. Methods for diagnosing and treating cancers related to this tumor suppressor, designated as TS10q23.3, also are disclosed.Type: ApplicationFiled: April 23, 2012Publication date: December 13, 2012Applicants: Myriad Genetics, Incorporated, Board of Regents, The University of Texas SystemInventors: Peter Steck, Mark A. Pershouse, Samar A. Jasser, Alfred W.K. Yung, Sean V. Tavtigian
-
Publication number: 20100190176Abstract: A specific region of chromosome 10 (10q23.3) has been implicated by series of studies to contain a tumor suppressor gene involved in gliomas, as well as a number of other human cancers. One gene within this region was identified, and the corresponding coding region of the gene represents a novel 47 kD protein. A domain of this product has an exact match to the conserved catalytic domain of protein tyrosine phosphatases, indicating a possible functional role in phosphorylation events. Sequence analyses demonstrated the a number of exons of the gene were deleted in tumor cell lines used to define the 10q23.3 region, leading to the classification of this gene as a tumor suppressor. Further analyses have demonstrated the presence of a number of mutations in the gene in both glioma and prostate carcinoma cells. Methods for diagnosing and treating cancers related to this tumor suppressor, designated as TS10q23.3, also are disclosed.Type: ApplicationFiled: April 1, 2010Publication date: July 29, 2010Applicants: Board of Regents, The University of Texas System, Myriad Genetics, IncorporatedInventors: Peter Steck, Mark A. Pershouse, Samar A. Jasser, Alfred W.K. Yung, Sean V. Tavtigian
-
Patent number: 7732576Abstract: A specific region of chromosome 10 (10q23.3) has been implicated by series of studies to contain a tumor suppressor gene involved in gliomas, as well as a number of other human cancers. One gene within this region was identified, and the corresponding coding region of the gene represents a novel 47 kD protein. A domain of this product has an exact match to the conserved catalytic domain of protein tyrosine phosphatases, indicating a possible functional role in phosphorylation events. Sequence analyses demonstrated the a number of exons of the gene were deleted in tumor cell lines used to define the 10q23.3 region, leading to the classification of this gene as a tumor suppressor. Further analyses have demonstrated the presence of a number of mutations in the gene in both glioma and prostate carcinoma cells. Methods for diagnosing and treating cancers related to this tumor suppressor, designated as TS10q23.3, also are disclosed.Type: GrantFiled: October 30, 2006Date of Patent: June 8, 2010Assignee: Board of Regents, The University of Texas SystemInventors: Peter Steck, Mark A. Pershouse, Samar A. Jasser, Alfred W. K. Yung, Sean V. Tavtigian
-
Patent number: 7217795Abstract: A specific region of chromosome 10 (10q23.3) has been implicated by series of studies to contain a tumor suppressor gene involved in gliomas, as well as a number of other human cancers. One gene within this region was identified, and the corresponding coding region of the gene represents a novel 47 kD protein. A domain of this product has an exact match to the conserved catalytic domain of protein tyrosine phosphatases, indicating a possible functional role in phosphorylation events. Sequence analyses demonstrated the a number of exons of the gene were deleted in tumor cell lines used to define the 10q23.3 region, leading to the classification of this gene as a tumor suppressor. Further analyses have demonstrated the presence of a number of mutations in the gene in both glioma and prostate carcinoma cells. Methods for diagnosing and treating cancers related to this tumor suppressor, designated as TS10q23.3, also are disclosed.Type: GrantFiled: November 19, 2002Date of Patent: May 15, 2007Assignees: Myriad Genetics, Inc., Board of Regents, The University of Texas SystemsInventors: Peter Steck, Mark A. Pershouse, Samar A. Jasser, Alfred W. K. Yung, Sean V. Tavtigian
-
Patent number: 7129040Abstract: A specific region of chromosome 10 (10q23.3) has been implicated by series of studies to contain a tumor suppressor gene involved in gliomas, as well as a number of other human cancers. One gene within this region was identified, and the corresponding coding region of the gene represents a novel 47 kD protein. A domain of this product has an exact match to the conserved catalytic domain of protein tyrosine phosphatases, indicating a possible functional role in phosphorylation events. Sequence analyses demonstrated the a number of exons of the gene were deleted in tumor cell lines used to define the 10q23.3 region, leading to the classification of this gene as a tumor suppressor. Further analyses have demonstrated the presence of a number of mutations in the gene in both glioma and prostate carcinoma cells. Methods for diagnosing and treating cancers related to this tumor suppressor, designated as TS10q23.3, also are disclosed.Type: GrantFiled: November 1, 2004Date of Patent: October 31, 2006Inventors: Peter Steck, Mark A. Pershouse, Samar A. Jasser, Alfred W. K. Yung, Sean V. Tavtigian
-
Patent number: 6844189Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human prostate cancer predisposing gene (HPC2), some alleles of which cause susceptibility to cancer, in particular prostate cancer. More specifically, the present invention relates to germline mutations in the HPC2 gene and their use in the diagnosis of predisposition to prostate cancer. The invention also relates to presymptomatic therapy of individuals who carry deleterious alleles of the HPC2 gene. The invention further relates to somatic mutations in the HPC2 gene in human prostate cancer and their use in the diagnosis and prognosis of human prostate cancer. Additionally, the invention relates to somatic mutations in the HPC2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers.Type: GrantFiled: November 5, 1999Date of Patent: January 18, 2005Assignees: Myriad Genetics, Inc., University of Utah Research Foundation, Hospital for Sick ChildrenInventors: Sean V. Tavtigian, David H.-F. Teng, Jacques Simard, Johanna M. Rommens, Lisa A. Cannon Albright, Susan L. Neuhausen
-
Publication number: 20030139324Abstract: A specific region of chromosome 10 (10q23.3) has been implicated by series of studies to contain a tumor suppressor gene involved in gliomas, as well as a number of other human cancers. One gene within this region was identified, and the corresponding coding region of the gene represents a novel 47 kD protein. A domain of this product has an exact match to the conserved catalytic domain of protein tyrosine phosphatases, indicating a possible functional role in phosphorylation events. Sequence analyses demonstrated the a number of exons of the gene were deleted in tumor cell lines used to define the 10q23.3 region, leading to the classification of this gene as a tumor suppressor. Further analyses have demonstrated the presence of a number of mutations in the gene in both glioma and prostate carcinoma cells. Methods for diagnosing and treating cancers related to this tumor suppressor, designated as TS10q23.3, also are disclosed.Type: ApplicationFiled: November 19, 2002Publication date: July 24, 2003Inventors: Peter Steck, Mark A. Pershouse, Samar A. Jasser, Alfred W.K. Yung, Sean V. Tavtigian
-
Publication number: 20030120052Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human prostate cancer predisposing gene (HPC2), some alleles of which cause susceptibility to cancer, in particular prostate cancer. More specifically, the present invention relates to germline mutations in the HPC2 gene and their use in the diagnosis of predisposition to prostate cancer. The invention also relates to presymptomatic therapy of individuals who carry deleterious alleles of the HPC2 gene. The invention further relates to somatic mutations in the HPC2 gene in human prostate cancer and their use in the diagnosis and prognosis of human prostate cancer. Additionally, the invention relates to somatic mutations in the HPC2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers.Type: ApplicationFiled: November 20, 2001Publication date: June 26, 2003Applicant: Myriad Genetics, Inc.Inventors: Sean V. Tavtigian, David H. F. Teng, Jacques Simard, Johanna M. Rommens
-
Publication number: 20030045704Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human prostate cancer predisposing gene (HPC2), some alleles of which cause susceptibility to cancer, in particular prostate cancer. More specifically, the present invention relates to germline mutations in the HPC2 gene and their use in the diagnosis of predisposition to prostate cancer. The invention also relates to presymptomatic therapy of individuals who carry deleterious alleles of the HPC2 gene. The invention further relates to somatic mutations in the HPC2 gene in human prostate cancer and their use in the diagnosis and prognosis of human prostate cancer. Additionally, the invention relates to somatic mutations in the HPC2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers.Type: ApplicationFiled: November 20, 2001Publication date: March 6, 2003Applicant: Myriad Genetics, Inc.Inventors: Sean V. Tavtigian, David H.F. Teng, Jacques Simard, Johanna M. Rommens
-
Publication number: 20030044959Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human prostate cancer predisposing gene (HPC2), some alleles of which cause susceptibility to cancer, in particular prostate cancer. More specifically, the present invention relates to germline mutations in the HPC2 gene and their use in the diagnosis of predisposition to prostate cancer. The invention also relates to presymptomatic therapy of individuals who carry deleterious alleles of the HPC2 gene. The invention farther relates to somatic mutations in the HPC2 gene in human prostate cancer and their use in the diagnosis and prognosis of human prostate cancer. Additionally, the invention relates to somatic mutations in the HPC2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers.Type: ApplicationFiled: November 20, 2001Publication date: March 6, 2003Applicant: Myriad Genetics, Inc.Inventors: Sean V. Tavtigian, David H.F. Teng, Jacques Simard, Johanna M. Rommens
-
Publication number: 20030027228Abstract: The present invention is directed to the MMSC1 gene, its protein product and the use of the protein to (i) detect mutant MMAC1 proteins, (ii) screen for drugs which can be used for suppressing tumor growth and (iii) identify proteins which interact with the MMAC1 gene or are involved in the tumor suppression pathway of the MMAC1 gene.Type: ApplicationFiled: December 3, 2001Publication date: February 6, 2003Inventors: Paul L. Bartel, Sean V. Tavtigian
-
Publication number: 20030008346Abstract: The present invention is directed to the MMSC1 gene, its protein product and the use of the protein to (i) detect mutant MMAC1 proteins, (ii) screen for drugs which can be used for suppressing tumor growth and (iii) identify proteins which interact with the MMAC1 gene or are involved in the tumor suppression pathway of the MMAC1 gene.Type: ApplicationFiled: December 3, 2001Publication date: January 9, 2003Applicant: Myriad Genetics, Inc.Inventors: Paul L. Bartel, Sean V. Tavtigian
-
Patent number: 6482795Abstract: A specific region of chromosome 10 (10q23.3) has been implicated by series of studies to contain a tumor suppressor gene involved in gliomas, as well as a number of other human cancers. One gene within this region was identified, and the corresponding coding region of the gene represents a novel 47 kD protein. A domain of this product has an exact match to the conserved catalytic domain of protein tyrosine phosphatases, indicating a possible functional role in phosphorylation events. Sequence analyses demonstrated the a number of exons of the gene were deleted in tumor cell lines used to define the 10q23.3 region, leading to the classification of this gene as a tumor suppressor. Further analyses have demonstrated the presence of a number of mutations in the gene in both glioma and prostate carcinoma cells. Methods for diagnosing and treating cancers related to this tumor suppressor, designated as TS10q23.3, also are disclosed.Type: GrantFiled: August 26, 1998Date of Patent: November 19, 2002Assignees: Myriad Genetics, Inc., Board of Regents, University of Texas SystemInventors: Peter Steck, Mark A. Pershouse, Samar A. Jasser, Alfred W. K. Yung, Sean V. Tavtigian
-
Publication number: 20020168752Abstract: The present invention is directed to the MMSC2 gene, its protein product and the use of the protein to (i) detect mutant MMAC1 proteins, (ii) screen for drugs which can be used for suppressing tumor growth and (iii) identify proteins which interact with the MMAC1 gene or are involved in the tumor suppression pathway of the MMAC1 gene.Type: ApplicationFiled: September 14, 2001Publication date: November 14, 2002Inventors: Paul L. Bartel, Sean V. Tavtigian
-
Patent number: 6465629Abstract: The present invention relates to the relation of the BRG1 gene (also called SNF2&agr;) to human cancers and its use in the diagnosis and prognosis of human cancer. The invention also relates to the therapy of human cancers which have a mutation in the BRG1 gene, including gene therapy, protein replacement therapy and protein mimetics. Finally, the invention relates to the screening of drugs for cancer therapy.Type: GrantFiled: March 23, 2000Date of Patent: October 15, 2002Assignee: Myriad Genetics, Inc.Inventors: Alexander K. C. Wong, Sean V. Tavtigian, David H. F. Teng
-
Publication number: 20020146711Abstract: The present invention is directed to the MMSC2 gene, its protein product and the use of the protein to (i) detect mutant MMAC1 proteins, (ii) screen for drugs which can be used for suppressing tumor growth and (iii) identify proteins which interact with the MMAC1 gene or are involved in the tumor suppression pathway of the MAMC1 gene.Type: ApplicationFiled: August 6, 2001Publication date: October 10, 2002Inventors: Paul L. Bartel, Sean V. Tavtigian
-
Patent number: 6444419Abstract: The present invention relates to the relation of the TMPRSS2 gene to human cancers and its use in the diagnosis and prognosis of human cancer. The invention also relates to the therapy of human cancers which have a mutation in the TMPRSS2 gene, including gene therapy, protein replacement therapy and protein mimetics. Finally, the invention relates to the screening of drugs for cancer therapy.Type: GrantFiled: October 18, 2000Date of Patent: September 3, 2002Assignee: Myriad Genetics, Inc.Inventors: Alexander K. C. Wong, Sean V. Tavtigian, David H. F. Teng
-
Patent number: 6440699Abstract: A human gene which is here named CA7 CG04 has been identified in which mutations have been found which have been correlated with prostate cancer.Type: GrantFiled: May 11, 2000Date of Patent: August 27, 2002Assignees: Myriad Genetics, Inc., Hospital for Sick Children, TheInventors: Sean V. Tavtigian, Brad Swedlund, Jacques Simard, Johanna M. Rommens